WHY Focus According to WHO research, cancer has become the world’s biggest killer. There are about 12 million newly increased cancer patients in the world every year. Antibodies are among the most important and most utilized molecular tools for Medicine and Research. Applications span the biomedical market sectors of Biotechnology, Pharmaceuticals & Therapeutic Drug Development and Research. Valued at over US$40 billion in 2010, the Antibody Market is driven overwhelmingly by monoclonal antibodies while this number is barely US$2 bn ten years ago. It is predicted that this significant expand will continue to reach US$50 bn in 2013.
Technology innovation plays an important role among those growth drivers. Emerging antibody product pipeline is enhanced by intensive R&D activities, filling with next generation antibodies, antibody fragments, antibody-drug conjugates, bio-better and biosilimars. Along with high specificity, monoclonal antibodies are effective in a broad range of diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation. Followed by the huge success of China Vaccine Focus 2011, CDMC will continue to provide a content-rich, critically-focused event with the aim of helping bioprocess decision makers and scientists obtain strategic solutions and technology breakthrough respectively. No other conference on the market provides a more comprehensive understanding of downstream bottlenecks especially therapeutics, upstream production & development, engineering & design, and pre-clinical & clinical results. |
.gif){kind=small}